Avanos Medical (AVNS) Capital Expenditures (2013 - 2026)

Avanos Medical (AVNS) has 14 years of Capital Expenditures data on file, last reported at $4.3 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 35.82% year-over-year to $4.3 million; the trailing twelve-month figure through Mar 2026 stood at -$800000.0 (down 109.76% YoY), and the FY2025 full-year result was $1.6 million, down 71.43% from the prior year.
• Capital Expenditures grew to $4.3 million in Q1 2026, from -$23.1 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $11.0 million in Q2 2025 to a low of -$23.1 million in Q4 2025.
• A 5-year average of $2.0 million and a median of $4.1 million in 2022 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures tumbled 323.4% in 2022 and soared 156.19% in 2023, its largest moves.
• Tracing AVNS's Capital Expenditures over 5 years: stood at -$10.5 million in 2022, then soared by 156.19% to $5.9 million in 2023, then sank by 225.42% to -$7.4 million in 2024, then plunged by 212.16% to -$23.1 million in 2025, then jumped by 118.61% to $4.3 million in 2026.
• Business Quant data shows AVNS's Capital Expenditures at $4.3 million in Q1 2026, -$23.1 million in Q4 2025, and $7.0 million in Q3 2025.